Loading company financials…
Nasdaq · In Vitro & In Vivo Diagnostic Substances · CIK 0000874716
$535.38
-3.53% · delayed 15 min
$42.68B market value
What this company does
IDEXX LABORATORIES /DE develops and makes medicines. It took in $4.30B last year, which makes it a mid-sized company. Of every dollar it sells, about 25 cents is left as profit.
Financial health
Strong finances across the board.
From IDEXX LABORATORIES INC /DE's FY2025 annual filing · share price scored separately
Every check behind the three models, and what each one tests
Measured against FY2024, from the 10-K
Improved: +10.4%
$3.90B to $4.30B
Improved: +19.3%
$887.9M to $1.06B
Improved: +1.8 pts
22.8% to 24.6%
It makes a profit rather than burning through money.
$1.06B earned last year
Day-to-day operations generate real cash, not just accounting profit.
$1.18B cash from operations
Its debt is small next to the cash the business produces.
about 0.2 years of cash flow to clear
It passes almost every standard check of financial strength.
Piotroski 8/9
Nothing in the filings stands out as a concern.
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 15% a year for the next 10 years. Over the last 10 years it grew by about 23% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 25 cents of every dollar of sales as profit, earning $1.06B last year.
What it earns, what it keeps, and what it costs to run — all from the same filing
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $1.06B and generated $1.18B of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Nothing recent
No insider trades, pending-sale notices or 5% stake filings from IDXX in the last few months. That is the ordinary case, not a gap.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Quarterly report(10-Q) | 2026-08-04 | 2026-06-30 |
| Major event announcement(8-K) | 2026-08-04 | 2026-08-04 |
Financial figures are from IDXX's 10-K for fiscal year 2025 (period ending 2025-12-31), reported under the US GAAP taxonomy. View the source filing.
8 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
20.06
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.49
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +30.8%
$808.1M to $1.06B
Improved: -16.7%
$449.8M to $374.8M
Deteriorated: -37.5%
$288.3M to $180.1M
Improved: -2.3%
81.6M to 79.7M
2 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 12% and 17%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 2.4% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Slowly. Sales grew 10.4% last year.
No. Its borrowings would take under a year of cash flow to clear. For every $1 it owes, it owns $1.92 in assets.
Expensive. Investors pay $40.3 for every $1 of yearly profit, so a lot of future growth is already priced in.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
At a glance
| Major event announcement(8-K) | 2026-05-15 | 2026-05-12 |
| Quarterly report(10-Q) | 2026-05-05 | 2026-03-31 |
| Major event announcement(8-K) | 2026-05-05 | 2026-05-05 |
| Shareholder voting information(DEF 14A) | 2026-03-27 | 2025-12-31 |
| Major event announcement(8-K) | 2026-03-26 | 2026-03-24 |
| Annual report(10-K) | 2026-02-20 | 2025-12-31 |
| Major event announcement(8-K) | 2026-02-13 | 2026-02-13 |
| Major event announcement(8-K) | 2026-02-02 | 2026-02-02 |
| Major event announcement(8-K) | 2026-01-13 | 2026-01-11 |
| Major event announcement(8-K) | 2025-11-13 | 2025-11-12 |
| Quarterly report(10-Q) | 2025-11-03 | 2025-09-30 |
| Major event announcement(8-K) | 2025-11-03 | 2025-11-03 |
| Major event announcement(8-K) | 2025-10-07 | 2025-10-06 |
| Quarterly report(10-Q) | 2025-08-04 | 2025-06-30 |
| Major event announcement(8-K) | 2025-08-04 | 2025-08-04 |
| Major event announcement(8-K) | 2025-07-10 | 2025-07-10 |
| Major event announcement(8-K) | 2025-05-09 | 2025-05-07 |
| Quarterly report(10-Q) | 2025-05-01 | 2025-03-31 |
Coverage from the last 30 days
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
Yahoo Finance ·
Are Wall Street Analysts Predicting IDEXX Laboratories Stock Will Climb or Sink?
Yahoo Finance ·
Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?
Yahoo Finance ·
Rationale Behind Baron Focused Growth Fund’s IDEXX Laboratories (IDXX) Holding
Yahoo Finance ·
Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?
Yahoo Finance ·
IDEXX (IDXX) Q2 2026 Earnings Call Transcript
Yahoo Finance ·
Here is Why Growth Investors Should Buy Idexx (IDXX) Now
Yahoo Finance ·
IDEXX Laboratories Q2 Earnings Call Highlights
Yahoo Finance ·
IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve
Yahoo Finance ·
Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?
Yahoo Finance ·
IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests
Yahoo Finance ·
IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
Yahoo Finance ·
Primary sources and further research